Home » Newsletters » BioWorld

BioWorld

Dec. 2, 1999

View Archived Issues

Other News To Note

Gilead Begins Enrollment Of Tenofovir DF Phase III Trial

Insmed Acquiring Celtrix In Deal To Broaden Pipeline, Go Public

Abgenix, HGS Agree To Align In Deal With Multiple Targets

Lyme Disease After-Symptoms Mimic Autoimmunity, Inspire Multiple Sclerosis Research

Titan's Schizophrenia Drug Positive In Initial Phase III

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 17, 2024.
Second insulin receptor offers new therapeutic avenues
BioWorld Science
Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...
Mechanism underlying so-called idiopathic autism inception unveiled
BioWorld Science
Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.